While COVID-19 only first emerged in 2019, influenza has been plaguing humanity for centuries. Since the 1918 influenza pandemic, vaccines, therapeutics, and diagnostics have improved our ability to prevent and protect against both seasonal and pandemic flu, and the COVID-19 pandemic has accelerated innovation across the entire biotechnology field. This panel will explore how novel vaccine, therapeutic, and diagnostic technologies are being applied to improve our ability to protect against seasonal influenza, with the conversation framed within the context of ongoing efforts as part of the US Government’s National Influenza Vaccine Modernization Strategy (NIVMS). Panelists from multiple companies will discuss how these novel technologies address the unique aspects of the influenza virus, avoid the problem of egg adaptation, and will highlight the regulatory and market challenges for advancing new influenza products. Panelists will also discuss the interface between seasonal flu and pandemic flu and how these platforms may be used for rapid response to the next flu pandemic.